« Back to Record
Citation APA

Scaltriti., M., Parra, J. L., Prudkin, L., Molina Jimenez, J., Aura, C. M., Harbeck, N., Pusztai, L., Ellis, C., Eidtmann, H., Arribas, J., Cortes, J., Nuciforo, P. G., de Azambuja, E., Piccart-Gebhart, M., Baselga, J., Bradbury, I., Sperinde, J., Agbor‑Tarh, D., Campbell, C., Chenna, A., Winslow, J., & Serra, V. (2015). High HER2 expression correlates with response to the combination of lapatinib and trastuzumab. Clinical cancer research, 21(3), 569-576. doi:10.1158/1078-0432.CCR-14-1824


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/231595

Scaltriti., M., Parra, J. L., Prudkin, L., Molina Jimenez, J., Aura, C. M., Harbeck, N., Pusztai, L., Ellis, C., Eidtmann, H., Arribas, J., Cortes, J., Nuciforo, P. G., de Azambuja, E., Piccart-Gebhart, M., Baselga, J., Bradbury, I., Sperinde, J., Agbor‑Tarh, D., Campbell, C., Chenna, A., Winslow, J., & Serra, V. (2015). High HER2 expression correlates with response to the combination of lapatinib and trastuzumab. Clinical cancer research, 21(3), 569-576. doi:10.1158/1078-0432.CCR-14-1824